β-neoendorphin (Human) [1278]
β-neoendorphin (Human)
| SMILES | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O |
| InChIKey | RTXIYIQLESPXIV-VLOLPVCOSA-N |
| Sequence | YGGFLRKYP |
| HELM | PEPTIDE1{Y.G.G.F.L.R.K.Y.P}$$$$ |
Chemical Properties
| Hydrogen bond acceptors | 14 |
| Hydrogen bond donors | 14 |
| Rotatable bonds | 32 |
| Log P | -1.586 |
| Molecular weight (Da) | 1099.6 |
| Stereochemistry info | unspecified |
Database connections
| Model (AF2) | κ |
Bioactivities
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein | Gene | Species | Family | Class | Type | Min | Avg | Max | Database |
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein | Gene | Species | Family | Class | Type | Min | Avg | Max | Database |
β-neoendorphin (Human)
Drug properties
| Molecular type | Peptide |
| Physiological/Surrogate | Endogenous |
| Approved drug | No |
Distribution across phases (no. indications)
Phase I
0
Phase II
0
Phase III
0
Phase IV
0
Database connections
| Model (AF2) | κ |